Watch today's Century Report podcast here:

https://www.youtube.com/watch?v=IAbGGVr5JKk

#AIDrugDiscovery #SolarEnergy #LithiumExt

Lilly signed a $2.75B deal for 28 AI-discovered drugs. A robot hit 100 MW of solar. The first U.S. lithium extraction plant went live. X-ray lasers captured a hidden phase of water. #AIDrugDiscovery #SolarEnergy #LithiumExt… sharedsapience.com/century-report/the-centu...

AI drug developer Insilico Medicine and Lilly ink commercialization deal worth up to $2.75 billion Lilly has signed a deal with AI drug developer Insilico that’s worth $115 million up front and approximately $2.75 billion in biobucks

Lilly partners with Insilico for a groundbreaking AI drug deal worth $2.75B! What potential do you see in AI for healthcare? #AIDrugDiscovery

www.statnews.com/2026/03/29/insilico-medi...

InSilico-Lilly Deal Valued Up to $2.75bn InSilico and Eli Lilly announced a deal on Mar 29, 2026 worth up to $2.75bn; the headline cap exceeds typical AI-pharma collaborations and hinges on clinical translation.

InSilico-Lilly Deal Valued Up to $2.75bn: InSilico and Eli Lilly announced a deal on Mar 29, 2026 worth up to $2.75bn; the headline cap exceeds typical AI-pharma collaborations and hinges on clinical… 👈 Read full analysis #InSilico #EliLilly #PharmaPartnership #AIDrugDiscovery #ClinicalTranslation

Watch today's Century Report podcast here:

https://www.youtube.com/watch?v=o6u2ggPgWks

#CleanEnergy #AIdrugdiscovery

U.S. grid batteries hit domestic self-sufficiency - zero to 96 GWh in 18 months. AI biologics platform raised $787M with 40+ drug programs. Heidelberg found Alzheimer's hidden death switch. #CleanEnergy #AIdrugdiscovery sharedsapience.com/century-report/the-centu...

AI vs. Aging: The End of the Human Expiration Date? 🧬 The Death of Death: Is Aging Just a Software Bug? 🛠️ What if I told you that you might be part of the last generation of humans destined to die from old age? In this mind-bending episode, we dive deep into the radical frontier of biotechnology where the world’s elite are no longer looking for a 'fountain of youth'—they are building it with code. We explore the controversial shift from viewing aging as an inevitable tragedy to treating it as a reparable software bug that can be patched, updated, and optimized. 🚀 The Race to Longevity Escape Velocity Driven by massive investments from Silicon Valley billionaires and the predictive power of Generative AI, we are rapidly approaching Longevity Escape Velocity. This is the tipping point where science extends your life expectancy by more than a year for every year you stay alive. In this episode, we break down: - 🧪 Cellular Reprogramming: How scientists are resetting biological clocks to 'factory settings.' - 🤖 Generative AI in BioScience: How AI is compressing 50 years of drug discovery into just a few months. - 💰 The Immortal Billionaires: Why the tech elite are obsessed with 'curing' death and what it means for the rest of us. - ⚖️ The Stagnation Paradox: If nobody dies, does human progress stop? We tackle the chilling philosophical warning about a world without new generations. 🧠 Why This Matters Now This isn't science fiction anymore; it’s a tangible reality. From AI-driven medicine to the ethics of immortality, the convergence of tech and biology is rewriting the human script. Whether you find it thrilling or terrifying, the anti-aging revolution is here, and it’s changing what it means to be human. Is a world without death a utopia or a biological prison? Join us as we pull back the curtain on the most significant scientific shift in human history. 🔗 Stay Ahead of the Future If you enjoyed this deep dive into the future of humanity, hit that Subscribe button and leave us a 5-star review! 🌟 Share this episode with the one person you want to live forever with. Let’s keep the conversation going—are you ready to live for 200 years? #BioTech #Longevity #AI #Immortality #FutureTech #AntiAging #GenerativeAI #SciencePodcast #LongevityEscapeVelocity  

📣 New Podcast! "AI vs. Aging: The End of the Human Expiration Date?" on @Spreaker #aidrugdiscovery #altoslabs #antiaging #aubreydegrey #biointelligence #biotech #cellularreprogramming #digitaltwins #epigenetics #futureofhealth #generativebiology #healthtech #immortality #lifeextension

Insilico and TaiGen Achieve Milestone in Collaboration: Out-Licensed CKD Anemia Candidate ISM4808 Completes first human enrollment and dosing in Phase I clinical trial – Company Announcement - FT.com The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting rights, and directors and dealings.

#AIDrugDiscovery #CKDAnemia #ClinicalTrials AI-driven CKD anemia candidate ISM4808 completes first human dosing in Phase I trial, advancing from discovery to clinic rapidly. markets.ft.com/data/announc...

Insilico Medicine and Liquid AI launch a secure, lightweight AI to streamline drug research and development.

vist.ly/4t2qv

#longevity #AIforDrugDiscovery #Biotech #PharmaInnovation #AIDrugDiscovery #HealthAI #DrugDevelopment

Quote on AI's limitations and creativity at AI in Drug Discovery Conference, London, 10 March, 2pm.

AI now shapes real R&D decisions—not just search results.

At #AIDrugDiscovery in London, Raul Cepin explores bias, blind spots, and how we build AI knowledge when evidence falls short.

📆 Mar 10 · 🕑 2 PM

Key takeaways to follow.

The $1 Billion Bet on AI That Could Redefine Drug Development and Pandemic Readiness

The next era of drug development is being shaped by AI, climate driven disease migration, aging populations and the hard lessons of COVID-19. #aidrugdiscovery

AI-powered drug discovery startup Peptris raised ₹70 Cr in Series A funding, co-led by IAN Alpha Fund and Speciale Invest, to boost clinical readiness and expand its pipeline.

#AIDrugDiscovery #BiotechFunding #Peptris #DeccanFounders #IANAlphaFund

Longevity biotech firm deepens UAE presence, linking AI drug discovery to national genomics and an emerging geroscience ecosystem.

vist.ly/4rrpk

#longevity #Juvenescence #AbuDhabi #UAEInnovation #AIDrugDiscovery #Genomics #BiotechInvestment #Geroscience

AI-Powered R&D Acceleration: Insilico Medicine and CMS announce multiple collaborations in central nervous system and autoimmune diseases /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), China...

#AIDrugDiscovery #Biotech Insilico Medicine & China Medical System partner on multiple projects for CNS & autoimmune diseases for faster target/molecule design with CMS's clinical & regulatory expertise to speed therapies to patients.
www.prnewswire.com/news-release...

The Isomorphic Labs Drug Design Engine unlocks a new frontier beyond AlphaFold - Isomorphic Labs Today, we are excited to share an update on our progress towards a new frontier of drug design. We have unlocked a new paradigm of predictive accuracy in understanding our biomolecular world, allowing...

Isomorphic Labs' Drug Design Engine #IsoDDE doubles AlphaFold 3 accuracy on novel protein-ligand structures, surpasses physics-based binding affinity predictions, identifies cryptic pockets from sequence alone, unlocking rational AI drug design www.isomorphiclabs.com/articles/the... #AIDrugDiscovery

Twist Bioscience shares rose after the company raised its fiscal 2026 revenue outlook and highlighted accelerating investment in AI-enabled discovery.

#TWST #TWSTStock #TwistBioscience #TwistBioscienceStock #AIDrugDiscovery

Reid Hoffman explains why he took the leap from founding software companies and investing in them to founding a healthcare AI company.

#AIdrugdiscovery #healthcareAI #drugdiscovery

AI News Wrap-Up: 16th January 2026 OpenAI tests ads + launches ChatGPT Go; Anthropic expands in India, warns on inequality; Nvidia-Lilly $1B drug AI; China closes gap. AI News.

AI News Wrap-Up: 16th January 2026

OpenAI tests ads + launches ChatGPT Go; Anthropic expands in India, warns on inequality; Nvidia-Lilly $1B drug AI; China closes gap

www.aiassistantstore.com/blogs/latest...

#AINews #ChatGPT #OpenAI #AIAdvertising #Anthropic #NVIDIA #AIDrugDiscovery

Chai Discovery's rapid rise from OpenAI roots to a $1.3B valuation and partnership with Eli Lilly showcases AI's transformative role in drug development. #AIDrugDiscovery #BiotechInnovation #ChaiDiscovery Link: thedailytechfeed.com/chai-discove...

AI-Assisted Discovery and Optimization of Small-Molecule TREM2 Agonists with Functional Microglial Activity Triggering receptor expressed on myeloid cells 2 (TREM2) is a microglia-specific receptor whose loss-of-function variants increase Alzheimer’s disease (AD) risk. While antibody-based agonists have sho...

AI-Assisted Discovery and Optimization of Small-Molecule TREM2 Agonists with Functional Microglial Activity pubs.acs.org/doi/10.1021/... @acs.org

#KellyChibale #AlzheimersDisease #Neurodegeneration #AIDrugDiscovery #MedicinalChemistry #Neuroscience #DrugDiscovery

Moves by a chipmaker and a pharma giant signal how AI is reshaping medicine and what it could mean for the future of longevity.

longevity.technology/news/nvidia-...

#longevity #AIDrugDiscovery #BioTech #AIinHealth #Innovation #FutureMedicine #TechXLife

Converge Bio raises $25M to accelerate AI-driven drug discovery, backed by Bessemer and tech leaders from Meta, OpenAI, and Wiz. #AIDrugDiscovery #BiotechInnovation #ConvergeBioFunding Link: thedailytechfeed.com/converge-bio...

Now Iktos teams up with Pierre Fabre in oncology As Servier announces its partnership with Paris, France-based Iktos, now Pierre Fabre Laboratories has revealed an integrated collaboration with Iktos

#Iktos #PierreFabre #oncology #PierreFabreLaboratories #AIdrugdiscovery #roboticsdrugdiscovery #smallmoleculedrugcandidates #generativeAI #EICAccelerator #PierreFabreMedicalCare #generativeAI #precisiononcology #NSCLC #nonsmallcelllungcancer #solidtumours #rarediseases
zurl.co/Gx2yL

Oxford Drug Design reports major in vivo milestone for novel cancer therapy - PharmaTimes Data shows potential route to overcoming resistance in aggressive colorectal tumours

#AIdrugdiscovery #drugdiscovery #RandD #oncology #OxfordDrugDesign #invivo #novelcancertherapy #aggressivecolorectaltumours #colorectaltumours #GenAIplatform #colorectalcancer #benchmarktherapy #KRASmutations #RASdrivencolorectalcancers #CRUKScotlandInstitute
zurl.co/tYDJO

US AI Drug Discovery Market Healthcare Systems Data 2035 US AI Drug Discovery Market share register 211.57 USD Million in 2024, projected to grow 25.15 % CAGR to reach USD Million 2494.89 during the forecast period 2025 - 2035.

AI is revolutionizing drug discovery in the US by reducing R&D time and cost. Discover market potential 👉 www.marketresearchfuture.com/reports/us-a...
#AIDrugDiscovery #PharmaTech

How AI Drug Discovery Is Transforming Modern Medicine and Healthcare How AI Drug Discovery Is Transforming Modern Medicine and Healthcare The pharmaceutical industry is witnessing an unprecedented transformation as artificial intelligence drug discovery reshapes how we develop life-saving medications. Traditional drug development has long been a costly, time-intensive process, often requiring over a decade and billions of dollars. Today, AI-powered platforms are accelerating this timeline dramatically while reducing costs and improving success rates. The Revolutionary Impact of AI on Pharmaceutical Research Artificial intelligence has emerged as a game-changer in modern medicine, transforming every stage of the drug discovery pipeline. From identifying novel therapeutic targets to predicting molecular properties, AI systems analyze vast datasets with unprecedented speed and accuracy. Machine learning algorithms can now process millions of chemical compounds in days—a task that would take human researchers years to complete manually. How AI Drug Discovery Is Transforming Modern Medicine and Healthcare The technology's impact extends beyond speed. Deep learning models can predict drug efficacy and toxicity with remarkable precision, significantly reducing the risk of costly late-stage clinical trial failures. This predictive power allows researchers to focus resources on the most promising candidates, optimizing the entire development process. Key Applications Driving AI Drug Discovery Forward Target Identification and Validation AI algorithms excel at analyzing complex biological data to identify disease-causing proteins and genetic pathways. By processing genomic data, medical literature, and clinical records simultaneously, AI systems uncover therapeutic targets that might otherwise remain hidden. DeepMind's AlphaFold, for instance, has predicted structures for over 200 million proteins, dramatically accelerating target validation. Molecular Design and Optimization Rather than screening existing compound libraries, modern AI platforms generate entirely new molecular structures from scratch. These generative models create drug candidates optimized for specific properties like bioavailability, selectivity, and minimal side effects. This de novo design approach opens possibilities that traditional chemistry could never achieve. Predictive Toxicology and Safety Assessment One of AI's most critical contributions lies in predicting drug safety profiles before expensive clinical trials begin. Machine learning models trained on historical toxicity data can flag potential safety concerns early, preventing dangerous compounds from advancing. This capability protects both patients and pharmaceutical companies from costly failures. Major Breakthroughs and Success Stories The real-world impact of AI-driven drug development is already evident. In 2020, Exscientia announced the first AI-designed molecule entering human trials. By 2022, Insilico Medicine achieved another milestone: beginning Phase I trials for a drug where both the molecule and its target were discovered entirely by AI—completing preclinical development in under 18 months compared to the industry average of 4-6 years. These successes aren't isolated incidents. Pharmaceutical companies have invested over $5.2 billion in AI drug discovery platforms, with investment doubling annually for five consecutive years. Major players like Pfizer, Novartis, and AstraZeneca have established AI research divisions, recognizing the technology's transformative potential. Challenges and Future Considerations Despite remarkable progress, AI drug discovery faces several challenges. Data quality remains paramount—algorithms are only as good as the information they're trained on. Biased or incomplete datasets can lead to flawed predictions, potentially overlooking effective treatments or advancing dangerous compounds. Regulatory frameworks are also evolving to address AI-discovered drugs. The FDA and other agencies are developing guidelines for evaluating AI-designed therapeutics, balancing innovation with patient safety. Questions about explainability—understanding how AI reaches its conclusions—remain central to regulatory approval processes. The Economic and Healthcare Impact The financial implications are staggering. According to Morgan Stanley, even modest improvements in drug development success rates could yield 50 additional therapies over ten years, representing a $50 billion market opportunity. For patients, this means faster access to treatments for diseases ranging from cancer to rare genetic disorders. AI-powered drug discovery particularly benefits rare disease research, where traditional methods often prove economically unviable. By dramatically reducing development costs, AI makes it financially feasible to pursue treatments for smaller patient populations, addressing previously neglected medical needs. Frequently Asked Questions How accurate is AI in predicting drug efficacy? Modern AI systems achieve 70-85% accuracy in predicting drug-target interactions, significantly outperforming traditional computational methods. Deep learning models continue improving as they process more clinical data. Will AI replace pharmaceutical researchers? No. AI serves as a powerful tool augmenting human expertise rather than replacing it. Scientists remain essential for interpreting results, designing experiments, and making critical decisions throughout development. How long before AI-discovered drugs become mainstream? Several AI-designed drugs are already in clinical trials, with the first approvals expected within 2-3 years. The technology is rapidly maturing, with mainstream adoption likely by 2030. What types of diseases benefit most from AI drug discovery? Cancer, neurodegenerative diseases, rare genetic disorders, and infectious diseases show particular promise. AI excels at identifying patterns in complex diseases where traditional approaches struggle. Looking Ahead: The Future of Medicine As computational power increases and datasets expand, AI's role in drug discovery will only grow. Emerging technologies like quantum computing promise even greater capabilities, potentially enabling real-time molecular simulations and personalized medicine at unprecedented scales. The convergence of AI with other technologies—genomics, proteomics, and electronic health records—creates a powerful ecosystem for precision medicine. Future drugs may be designed specifically for individual patients' genetic profiles, maximizing efficacy while minimizing side effects. The revolution in pharmaceutical research isn't coming—it's already here. As AI continues advancing, we stand at the threshold of a new era in medicine where life-saving treatments reach patients faster, cheaper, and more effectively than ever imagined. 📢 Found this article helpful? Share it with colleagues and friends working in healthcare, pharmaceuticals, or technology. Together, we can spread awareness about how AI is transforming medicine and saving lives. Use the share buttons below to post on your social networks! { "@context": "https://schema.org", "@type": "Article", "headline": "How AI Drug Discovery Is Transforming Modern Medicine and Healthcare", "description": "Discover how artificial intelligence is revolutionizing pharmaceutical research and drug development. Learn about AI's impact on target identification, molecular design, clinical trials, and the future of personalized medicine in this comprehensive guide.", "image": "https://sspark.genspark.ai/cfimages?u1=kEiX4Y%2F5ZGZDjU2H3w8mwo3OV%2BWUnKdnyyZqLV5UvDS1sms%2BRNpKBGgZDdhi8YtLMxKjHqNjGBcVApwb2lQJbAiO9%2BIA6%2FdLxL6XPa5KopWtxEM891XuzhaqrhuxxBwsk3TXhDiZuU0KYFgX80N0s8phbEGmYA1AwWkHt1zddQ%3D%3D&u2=ZJ%2Bi4%2BUShbYUQ449&width=2560", "author": { "@type": "Organization", "name": "YourSiteName" }, "publisher": { "@type": "Organization", "name": "YourSiteName", "logo": { "@type": "ImageObject", "url": "https://www.yoursite.com/logo.png" } }, "datePublished": "2025-12-21", "dateModified": "2025-12-21", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://www.yoursite.com/ai-drug-discovery" } } Thank you for reading. Visit our website for more articles: https://www.proainews.com

How AI Drug Discovery Is Transforming Modern Medicine and Healthcare #AIDrugDiscovery #PharmaceuticalInnovation #HealthcareRevolution #ArtificialIntelligence #ModernMedicine

AI-guided simulations identified a key viral entry interaction, blocking herpes infection in lab tests and pointing to future antivirals that stop viruses before they enter cells.

#AIDrugDiscovery

Gabe Musso (CSO, BioSymetrics) at PMWC 2026 Silicon Valley, March 4-6, 2026

Gabe Musso (CSO, BioSymetrics, a @lunaibioworks.com company) will speak at PMWC 2026 Silicon Valley on Mar 6 with a talk titled “Closing the Loop: Coupling AI with In Vivo Validation.” #PMWC2026 #AIDrugDiscovery #AIinMedicine

Boosting R&D Efficiency With AI Drug Discovery Explore how AI-driven drug discovery boosts R&D efficiency, accelerates innovation, and reduces costs in modern pharmaceutical development.

Boosting R&D Efficiency with AI Drug Discovery

read more : bi-journal.com/boosting-ai-...

#AIdrugdiscovery #ResearchandDevelopment #BIJournal #BIJournalnews #BusinessInsightsarticles #BIJournalinterview